A new policy report from the American Urological Association (AUA) advises physicians on the best use of prostate-specific antigen (PSA) testing in the diagnosis and management of prostate cancer.
"The report cuts to the quick of what we actually know about the PSA test, thereby helping to eliminate many commonly performed procedures used to diagnose, stage, and monitor prostate cancer," said Ian Thompson, MD, of the University of Texas, San Antonio, Medical Center, and chair of the AUA committee that developed the policy.
Voelker R. New Guidance on PSA Testing. JAMA. 2000;283(12):1557. doi:10.1001/jama.283.12.1557